TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05908786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 mg by IV infusion on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobemstomig
Description: Tobemstomig will be administered at a dose of 600 mg by IV infusion on Day 1
Study: NCT05520190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Treatment Seeking (CBT-TS)
Description: The intervention will consist of 1 - 2 sessions. The first session is approximately 60 - 90 minutes and will be structured in 4 phases 1) subject's history of symptoms and current functioning, 2) their coping methods, 3) modification of treatment beliefs, 4) action planning. The interventionist will provide the subject with a list of resources for seeking treatment.~All subjects will be offered an optional second session with the interventionist. The second session will consist of a 60-minute appointment focused on providing practical assistance to identify available treatment options in the subject's area, scheduling treatment sessions, and problem-solving barriers to treatment.
Study: NCT06482294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticason either Beclometasone or Budesonide
Description: One arm is a combination of salbutamol and an ICS as a rescue medication (anti-inflammatory rescue medication). The second arm is salbutamol only as a rescue medication (non-anti-inflammatory rescue medication).
Study: NCT06095089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-78278343
Description: JNJ-78278343 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-87189401
Description: JNJ-87189401 will be administered.
Study: NCT05400369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitafloxacin
Description: Oral administration, 50 mg tablets
Study: NCT05272228

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplement - standard product
Description: Single dose intervention with Standard product Coenzyme Q10 (ubiquinone) 2 capsules - 100 mg total coenzyme Q10
Study: NCT05400369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Hydrochloride
Description: Oral administration, 400 mg tablets
Study: NCT05936684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing with prolonged exhalation (ProlEx) during risky decision-making
Description: 20 min divided in 3 blocks of slow, 0.1 Hz breathing (6 cycles per minute) with an inhalation-to-exhalation ratio of 2:8. Cue-assisted breathing (same across participants) and performance of a risky decision-making task (Tom et al., 2007) in the magnetic resonance imaging (MRI) scanner with simultaneous acquisition of physiological and pupil data.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing with prolonged exhalation (ProlEx) during risky decision-making
Description: 20 min divided in 3 blocks of slow, 0.1 Hz breathing (6 cycles per minute) with an inhalation-to-exhalation ratio of 2:8. Cue-assisted breathing (same across participants) and performance of a risky decision-making task (Tom et al., 2007) in the magnetic resonance imaging (MRI) scanner with simultaneous acquisition of physiological and pupil data.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal breathing (Eupnea/Control) during risky decision-making
Description: 20 min divided in 3 blocks of normal breathing (expected range: 0.16-0.33 Hz, i.e., 10-20 per min), Cue-assisted breathing (individually adapted) and performance of a risky decision-making task (Tom et al., 2007) in the MRI scanner with simultaneous acquisition of physiological and pupil data.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal breathing (Eupnea/Control) during risky decision-making
Description: 20 min divided in 3 blocks of normal breathing (expected range: 0.16-0.33 Hz, i.e., 10-20 per min), Cue-assisted breathing (individually adapted) and performance of a risky decision-making task (Tom et al., 2007) in the MRI scanner with simultaneous acquisition of physiological and pupil data.
Study: NCT05550415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40mg
Description: The administration of Simvastatin 40 mg in addition to ACT regiment of neoadjuvant chemotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The administration of Placebo capsule 40 mg in addition to ACT regiment of neoadjuvant chemotherapy
Study: NCT05841758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine (200-400 mg /day during a 12 months double blind placebo-controlled period)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo during a 12 months double blind placebo-controlled period
Study: NCT05449548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg
Description: All subjects will be treated with lenalidomide 10mg/day with a regular follow-up of 12 weeks, followed by a 4-week observation after cessation of lenalidomide.
Study: NCT05485961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL300
Description: Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL300
Description: Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL300
Description: Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL300
Description: Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% w/v NaCl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 2 (Phase 3): Matching the excipient content and concentration of the CSL300 product, minus the active ingredient
Study: NCT06207877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Cagrilintide will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide will be administered subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.
Study: NCT05094167

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: V9
Description: one times a day during the whole treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT06342986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT536
Description: FT536 is an allogeneic natural killer (NK)-cell immunotherapy produced from a clonal master humaninduced pluripotent stem cell (iPSC) line.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT536
Description: FT536 is an allogeneic natural killer (NK)-cell immunotherapy produced from a clonal master humaninduced pluripotent stem cell (iPSC) line.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT536
Description: FT536 is an allogeneic natural killer (NK)-cell immunotherapy produced from a clonal master humaninduced pluripotent stem cell (iPSC) line.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT536
Description: FT536 is an allogeneic natural killer (NK)-cell immunotherapy produced from a clonal master humaninduced pluripotent stem cell (iPSC) line.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2 IV given on day -5. Given consecutively with CY.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2 IV given on day -5. Given consecutively with CY.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2 IV given on day -5. Given consecutively with CY.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2 IV given on day -5. Given consecutively with CY.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CY
Description: CY 300 mg/m2 IV given on day -4. Given consecutively with Fludarabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CY
Description: CY 300 mg/m2 IV given on day -4. Given consecutively with Fludarabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CY
Description: CY 300 mg/m2 IV given on day -4. Given consecutively with Fludarabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CY
Description: CY 300 mg/m2 IV given on day -4. Given consecutively with Fludarabine.
Study: NCT06374940

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Manipulator-assisted Abdominal Hysterectomy
Description: Manipulator-assisted Abdominal Hysterectomy
Study: NCT05272228

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement - Investigational product IP1
Description: Single dose intervention with Investigational product IP1; Q10 MICROENCAPSULATED 2 capsules - 100 mg total coenzyme Q10

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement - Investigational product IP2
Description: Single dose intervention with Investigational product IP2; Final formulated product BQSM® 2 capsules - 100 mg total coenzyme Q10
Study: NCT06108245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Values Clarification Mobile Application
Description: Participants in the intervention group will be asked to answer a series of values clarification writing prompts twice a day over four weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Self-Reflection Mobile Application
Description: Participants in the psychological placebo group will be administered writing prompts in the same format and frequency as the values intervention, but with prompts focused on self-reflection related to clutter and organization.
Study: NCT04990830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Low molecular weight heparin
Description: Application with Soft Mist Inhaler

Intervention type: DRUG
Group type: OTHER
Intervention: Standard Treatment
Description: Control Group
Study: NCT05067257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resiniferatoxin
Description: Resiniferatoxin is a compound purified from natural sources

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle solution
Study: NCT05083650

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Macular hole closure with amniotic membrane with/without internal limiting membrane peeling
Description: Pars plana vitrectomy with/without internal limiting membrane peeling, amniotic membrane, and air tamponade

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Macular hole closure with amniotic membrane with/without internal limiting membrane peeling
Description: Pars plana vitrectomy with/without internal limiting membrane peeling, amniotic membrane, and air tamponade
Study: NCT06298435

Intervention type: PROCEDURE
Intervention: Intermittent Positive pressure ventilation
Description: Intermittent positive pressure ventilation during general anesthesia for non-cardiac surgery
Study: NCT06057883

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: A blend of two probiotic strains. Participants will take 1 capsule daily at 3 billion Colony Forming Units (CFUs)
Study: NCT05692882

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stents
Description: The NOVA stent is a sirolimus-eluting stent system designed for intracranial artery stenosis with a rapid exchangeable balloon
Study: NCT04571723

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Prevention Program
Description: This is the established Diabetes prevention program curriculum.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Mindset modified diabetes prevention program
Description: This is the established diabetes prevention program curriculum with the addition of curriculum focused on the role of mindset in health.
Study: NCT06504472

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProstaThrive™ Supplement
Description: Participants in this arm will take three ProstaThrive™ capsules daily after the final meal of the day for 90 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this arm will take three placebo capsules daily after the final meal of the day for 90 days. The placebo capsules will contain an inert substance that mimics the appearance of the ProstaThrive™ supplement.
Study: NCT05050409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief mindfulness
Description: A 15-minute guided mindfulness practice that includes focused attention on breath and body sensations and open monitoring and acceptance of thoughts, emotions, and pain.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief mindfulness
Description: A 15-minute guided mindfulness practice that includes focused attention on breath and body sensations and open monitoring and acceptance of thoughts, emotions, and pain.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief mindfulness
Description: A 15-minute guided mindfulness practice that includes focused attention on breath and body sensations and open monitoring and acceptance of thoughts, emotions, and pain.
Study: NCT06425991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered subcutaneously.
Study: NCT05424822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-80948543
Description: JNJ-80948543 will be administered as SC or IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-80948543
Description: JNJ-80948543 will be administered as SC or IV injection.
Study: NCT05492825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Each yoga class will follow a standardized structure, allowing participants to easily re-join if they miss classes. Yoga classes will be adapted to the abilities and limitations of each study participant, for example, using a chair for sitting exercises rather than the floor and to assist with balance. Postures (asanas) will target back pain and include mindfulness, relaxation, and breathing practices integral to hatha yoga, with focus on breath-based movement throughout. Each group will have 1-2 yoga instructors and no more than 5 participants per yoga instructor (up to 10 participants/group).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: The assessment at the second screening visit by the Physical Medicine \& Rehabilitation physician/Physical Therapy staff will be available to physical therapists in the Electronic Health Record and will guide the type of exercises, to focus on stabilization (strengthening core trunk muscles) and flexion or extension exercises. Sessions are divided into 30 minutes of working directly with a physical therapist and 30 minutes of supervised aerobic exercise (on treadmill or recumbent bike). Participants will receive a guidebook for guiding and recording home practice, based on Saper's guidebook and modified based on feedback from experts and stakeholders for clarity and cultural appropriateness.
Study: NCT05050409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement (MORE)
Description: An 8-session intervention. Sessions involve: 1) mindfulness training to reduce pain and increase self-regulation over opioid use, 2) cognitive reappraisal to decrease psychological distress, and 3) savoring to augment natural reward processing, positive emotion, and esprit de corps.
Study: NCT05492825

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment As Usual
Description: Participants in the Treatment As Usual group will receive routine clinical care. This includes: 1) pain assessment using a 10-point scale, at OTP admission and annual physical exams. This is documented on a templated form in the OTP electronic health record, as well as whether pain is acute vs chronic pain, and a treatment plan (e.g., on-site care, outside primary care clinician, pain management referral). 2) clinical treatment of pain by participants' on-site or outside clinicians. Those patients who receive on-site medical care have the opportunity to address nonpharmacological and pharmacological treatment with onsite physicians and physician assistants, and to receive referral to specialty care including physical therapy and orthopedics at multiple Montefiore locations throughout the Bronx.
Study: NCT05050409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement (MORE)
Description: An 8-session intervention. Sessions involve: 1) mindfulness training to reduce pain and increase self-regulation over opioid use, 2) cognitive reappraisal to decrease psychological distress, and 3) savoring to augment natural reward processing, positive emotion, and esprit de corps.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Preoperative Standard Care. Patients will attend a 2-hour preoperative class involving pain coping education and are offered prehabilitation services. Postoperative standard care includes (1) pain medications to minimize opioid use, including acetaminophen, lyrica, meloxicam/naproxen and celebrex, and (2) anticoagulants for 3-6 weeks postoperatively, as well as (3) ambulatory care with assistive devices 1-6 weeks after surgery. Patients see their surgeon postoperatively 2-6 weeks after surgery, 3-6 months, and yearly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Preoperative Standard Care. Patients will attend a 2-hour preoperative class involving pain coping education and are offered prehabilitation services. Postoperative standard care includes (1) pain medications to minimize opioid use, including acetaminophen, lyrica, meloxicam/naproxen and celebrex, and (2) anticoagulants for 3-6 weeks postoperatively, as well as (3) ambulatory care with assistive devices 1-6 weeks after surgery. Patients see their surgeon postoperatively 2-6 weeks after surgery, 3-6 months, and yearly.
Study: NCT05290844

Intervention type: OTHER
Group type: OTHER
Intervention: cricoid pressure
Description: cricoid force in pediatric patients
Study: NCT06520943

Intervention type: OTHER
Intervention: blood gas analysis
Description: 1. Airway pressure (P plateau, Ppeak) values are taken from the anesthesia device data,~2. BIS (from routine BIS monitoring)~3. Temperature (routinely from pharyngeal temperature probe),~4. Oxygen saturation (routinely from the patient monitor)~5. End-tidal CO₂,~6. inspiratory O₂ concentration,~7. Inspiratory CO2 concentration,~8. inspiratory and expiratory desflurane concentrations,~9. tidal volume,~10. MAC is routinely obtained from anesthesia device data.~11. Blood Gas Analysis (COHgb, Ph, PO2, PCO2, SaO2, HCO3, Base deficit, glucose, lactate)

Intervention type: OTHER
Intervention: blood gas analysis
Description: 1. Airway pressure (P plateau, Ppeak) values are taken from the anesthesia device data,~2. BIS (from routine BIS monitoring)~3. Temperature (routinely from pharyngeal temperature probe),~4. Oxygen saturation (routinely from the patient monitor)~5. End-tidal CO₂,~6. inspiratory O₂ concentration,~7. Inspiratory CO2 concentration,~8. inspiratory and expiratory desflurane concentrations,~9. tidal volume,~10. MAC is routinely obtained from anesthesia device data.~11. Blood Gas Analysis (COHgb, Ph, PO2, PCO2, SaO2, HCO3, Base deficit, glucose, lactate)
Study: NCT05373797

Intervention type: BEHAVIORAL
Intervention: Procedures performed on the experimental and control groups
Description: Intervention Group:26 Control Group (n=26):
Study: NCT06439940

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample extraction
Description: We do not alter the patient\&#39;s regular gynecological check-up in any way. The patient will undergo a mammogram and a blood draw. We will then separate a small aliquot of blood for the purposes of the research protocol.
Study: NCT05239325

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: World Cancer Day Walk
Description: Health literacy education (cancer prevention and healthy lifestyle) and free breast, prostate, cervical cancer screening
Study: NCT05305014

Intervention type: DIAGNOSTIC_TEST
Intervention: blood inflammatory markers (TNF-α, IL1ra, RsIL-2, IL-6, IL-10, IL-18, IFNγ, MCP-1/CCL2 GFAP)
Description: Bioassays of blood inflammatory markers (TNF-α, IL1ra, RsIL-2, IL-6, IL-10, IL-18, IFNγ, MCP-1/CCL2 GFAP) from sera babcocked in the HYCORE mother study.
Study: NCT06184243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training
Description: Parent training will cover the topic of creating social skills, goal setting, creating a video model, how to implement the video model intervention, and the parent-child interaction procedures during play. Parents will learn the steps in the fidelity checklist and demonstrate the steps at 90% proficiency by the end of the training. Parent coaching will continue before and after child intervention sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Modeling
Description: The child will be recorded for a video model engaging in play at their home. The videos will be created with the parent and researcher in the home. A video using the same materials in the same location will be created depicting the child in a play scenario. The video will be two-to-three minutes in length. Each child will receive at least three sessions of intervention and no more than five sessions of intervention per week.
Study: NCT06260735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trans-spinal electrical stimulation
Description: Trans-spinal electrical stimulation (ts-ES) at T11-L1 vertebral levels with short pulses at a set frequency (30Hz).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical muscle activation
Description: Peripheral nerve (PN) or muscle (NMES) stimulation strategy was developed for each participant to optimize stance/walk capacity based on personal needs/preferences.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill walking
Description: Stepping on a treadmill with individually preferred speed.